HONOLULU — Once daily netarsudil is an “excellent addition” to glaucoma treatments, Janet B. Serle, MD, said at the Association for Research in Vision and Ophthalmology meeting here. The treatment is now available in the U.S.
The rho kinase inhibitor netarsudil 0.02% (Rhopressa, Aerie Pharmaceuticals) lowers IOP and is well tolerated, she told Healio.com/OSN, explaining a poster presentation of the ROCKET 2 study.
The once daily administration addresses compliance and the novel mechanism acts by enhancing outflow at the tissue that is altered in glaucoma — the trabecular
Uncategorized